Caris Life Sciences, Inc. Common Stock (CAI) is next scheduled to report earnings on Aug 11, 2026. The consensus analyst EPS estimate for the upcoming quarter is $-0.01.
Heading into this report, the model's fair value estimate sits 41.1% below the current price (model fair value differential above current price). Descriptive context only — not a forecast of the earnings result.
Equity Rank computed model fair value for CAI from 6 independent valuation methods with sufficient data. 1 place fair value above the current price of $18.47, and 5 place it below. The model-blended estimate lands at $26.07 — a model fair value differential of 41.1% above the current price under these model assumptions. The larger group places fair value below the current price.
Equity Rank's fundamental strength composite scores CAI at 65.6/100 (B, Solid), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, gross margin has moved +35.4 pp.
Caris Life Sciences, Inc. Common Stock (CAI) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator